NCT06150664 - A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2026

Conditions

Non Small Cell Lung CancerTriple Negative Breast CancerHodgkin LymphomaHead and Neck Squamous Cell CarcinomaMalignant Melanoma

Interventions

DRUG

CTX-8371

Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.

Trial Locations (7)

RECRUITING

Roswell Park Cancer Institute, Buffalo

RECRUITING

Florida Cancer Specialists - Lake Nona, Orlando

RECRUITING

D&H Cancer Research Center, Margate

RECRUITING

Florida Cancer Specialists - Sarasota, Sarasota

RECRUITING

Tennessee Oncology, Nashville

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston